Early Stage Drug Treatment That Normalizes Proinflammatory Cytokine Production Attenuates Synaptic Dysfunction in a Mouse Model That Exhibits Age-Dependent Progression of Alzheimer's Disease-Related Pathology
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Overproduction of proinflammatory cytokines in the CNS has been implicated as a key contributor to pathophysiology progression in Alzheimer's disease (AD), and extensive studies with animal models have shown that selective suppression of excessive glial proinflammatory cytokines can improve neurologic outcomes. The prior art, therefore, raises the logical postulation that intervention with drugs targeting dysregulated glial proinflammatory cytokine production might be effective disease-modifying therapeutics if used in the appropriate biological time window. To test the hypothesis that early stage intervention with such drugs might be therapeutically beneficial, we examined the impact of intervention with MW01-2-151SRM (MW-151), an experimental therapeutic that selectively attenuates proinflammatory cytokine production at low doses. MW-151 was tested in an APP/PS1 knock-in mouse model that exhibits increases in AD-relevant pathology progression with age, including increases in proinflammatory cytokine levels. Drug was administered during two distinct but overlapping therapeutic time windows of early stage pathology development. MW-151 treatment attenuated the increase in microglial and astrocyte activation and proinflammatory cytokine production in the cortex and yielded improvement in neurologic outcomes, such as protection against synaptic protein loss and synaptic plasticity impairment. The results also demonstrate that the therapeutic time window is an important consideration in efficacy studies of drugs that modulate glia biological responses involved in pathology progression and suggest that such paradigms should be considered in the development of new therapeutic regimens that seek to delay the onset or slow the progression of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Long-Term Potentiation--A Decade of Progress?
Malenka, R. C., & Nicoll, A. R. A. (1999) · Science · doi:10.1126/science.285.5435.1870 · Cited by 2,729
Microglial physiology: unique stimuli, specialized responses
Ransohoff, R. M., & Perry, V. H. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132528 · Cited by 1,858 · cited 1×
“For example, astrocytes and microglia interact with neurons at the synapse to modulate synaptic function and plasticity (Eroglu and Barres, 2010; Tremblay et al., 2011) and are also vital for host defense mechanisms and response to stress (Ransohoff and Perry, 2009).”
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 1×
“…is compounded by the complexity of this multifactorial disease, the multiple roles of glia in homeostasis and host defense, and the diversity of inflammatory and immune response mechanisms (Nelson et al., 2009, 2011; Cameron and Landreth, 2010; Huang and Mucke, 2012; Wyss-Coray and Rogers, 2012).”
Immune modulation of learning, memory, neural plasticity and neurogenesis
Yirmiya, R., & Goshen, I. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.015 · Cited by 1,483
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 2×
“, 2012), and epidemiological and population-based clinical studies that suggest an association between early use of nonsteroidal anti-inflammatory drugs (NSAIDs) and reduced risk of developing AD (McGeer et al., 1996; in’t Veld et al., 2001; Zandi and Breitner, 2001).”
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
In-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 1×
“This is consistent with many studies demonstrating that glial activation and neuroinflammation are early events in AD pathogenesis (e.g., see Cagnin et al., 2001; Mrak and Griffin, 2005; Griffin and Barger, 2010; Carter et al., 2012), recent genome-wide association study data showing that many of…”
The Role of Microglia in the Healthy Brain: Figure 1.
Tremblay, M.-È., Stevens, B., Sierra, A., Wake, H., Bessis, A., & Nimmerjahn, A. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4158-11.2011 · Cited by 992 · cited 1×
“For example, astrocytes and microglia interact with neurons at the synapse to modulate synaptic function and plasticity (Eroglu and Barres, 2010; Tremblay et al., 2011) and are also vital for host defense mechanisms and response to stress (Ransohoff and Perry, 2009).”
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 1×
“…is compounded by the complexity of this multifactorial disease, the multiple roles of glia in homeostasis and host defense, and the diversity of inflammatory and immune response mechanisms (Nelson et al., 2009, 2011; Cameron and Landreth, 2010; Huang and Mucke, 2012; Wyss-Coray and Rogers, 2012).”
Regulation of synaptic connectivity by glia.
Eroglu, C., & Barres, B. A. (2010) · Nature · doi:10.1038/nature09612 · Cited by 813 · cited 1×
“For example, astrocytes and microglia interact with neurons at the synapse to modulate synaptic function and plasticity (Eroglu and Barres, 2010; Tremblay et al., 2011) and are also vital for host defense mechanisms and response to stress (Ransohoff and Perry, 2009).”
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Nelson, P. T., Braak, H., & Markesbery, W. R. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181919a48 · Cited by 643 · cited 1×
“…is compounded by the complexity of this multifactorial disease, the multiple roles of glia in homeostasis and host defense, and the diversity of inflammatory and immune response mechanisms (Nelson et al., 2009, 2011; Cameron and Landreth, 2010; Huang and Mucke, 2012; Wyss-Coray and Rogers, 2012).”
The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective
Shaftel, S. S., Griffin, W. S. T., & O'Banion, M. K. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-7 · Cited by 565
Kitazawa, M., Cheng, D., Tsukamoto, M. R., Koike, M. A., Wes, P. D., Vasilevko, V., Cribbs, D. H., & LaFerla, F. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100620 · Cited by 473
Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., & Landreth, G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07504.2003 · Cited by 469
Carter, S. F., Schöll, M., Almkvist, O., Wall, A., Engler, H., Långström, B., & Nordberg, A. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.087031 · Cited by 442 · cited 1×
“…and neuroinflammation are early events in AD pathogenesis (e.g., see Cagnin et al., 2001; Mrak and Griffin, 2005; Griffin and Barger, 2010; Carter et al., 2012), recent genome-wide association study data showing that many of the genes associated with increased AD risk are…”
He, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R., & Shen, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200705042 · Cited by 390 · cited 1×
“Some studies have reported that interference with cytokine signaling by anti-inflammatory drug treatment or genetic deletion strategies results in reduced amyloid plaque load (Lim et al., 2000; Jantzen et al., 2002; Yan et al., 2003; Morihara et al., 2005; He et al., 2007; Yamamoto et al., 2007).”
Yamamoto, M., Kiyota, T., Horiba, M., Buescher, J. L., Walsh, S. M., Gendelman, H. E., & Ikezu, T. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060378 · Cited by 367
Nelson, P. T., Head, E., Schmitt, F. A., Davis, P. R., Neltner, J. H., Jicha, G. A., Abner, E. L., Smith, C. D., Van Eldik, L. J., Kryscio, R. J., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0826-y · Cited by 365
Self-citationThe genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE
Guerreiro, R. J., Gustafson, D. R., & Hardy, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.025 · Cited by 285 · cited 2×
“…genome-wide association study data showing that many of the genes associated with increased AD risk are inflammation-related (Sleegers et al., 2010; Guerreiro et al., 2012), and epidemiological and population-based clinical studies that suggest an association between early use of nonsteroidal…”
The age-related attenuation in long-term potentiation is associated with microglial activation
Griffin, R., Nally, R., Nolan, Y., McCartney, Y., Linden, J., & Lynch, M. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04165.x · Cited by 282
AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice
Chang, E. H., Savage, M. J., Flood, D. G., Thomas, J. M., Levy, R. B., Mahadomrongkul, V., Shirao, T., Aoki, C., & Huerta, P. T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507313103 · Cited by 225 · cited 2×
“…also exhibits progressive pathological alterations in bidirectional synaptic plasticity, cognitive measures, synaptosomal membrane lipids, and oxidative stress markers as a function of animal development and maturation (Anantharaman et al., 2006; Chang et al., 2006; Bruce-Keller et al., 2011).”
Reaume, A. G., Howland, D. S., Trusko, S. P., Savage, M. J., Lang, D. M., Greenberg, B. D., Siman, R., & Scott, R. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23380 · Cited by 150
Siman, R., Reaume, A. G., Savage, M. J., Trusko, S., Lin, Y.-G., Scott, R. W., & Flood, D. G. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-23-08717.2000 · Cited by 133
The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects
Sleegers, K., Lambert, J.-C., Bertram, L., Cruts, M., Amouyel, P., & Van Broeckhoven, C. (2010) · Trends in Genetics · doi:10.1016/j.tig.2009.12.004 · Cited by 129
Xing, B., Bachstetter, A. D., & Van Eldik, L. J. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-84 · Cited by 101 · cited 1×
“Levels of synaptic proteins were measured by Western blots as described previously (Xing et al., 2011).”
Self-citationCognitive impairment in humanized APP×PS1 mice is linked to Aβ1–42 and NOX activation
Bruce-Keller, A. J., Gupta, S., Knight, A. G., Beckett, T. L., McMullen, J. M., Davis, P. R., Murphy, M. P., Van Eldik, L. J., St Clair, D., & Keller, J. N. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.07.012 · Cited by 96 · cited 1×
“…also exhibits progressive pathological alterations in bidirectional synaptic plasticity, cognitive measures, synaptosomal membrane lipids, and oxidative stress markers as a function of animal development and maturation (Anantharaman et al., 2006; Chang et al., 2006; Bruce-Keller et al., 2011).”
Cited by
Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases
Tang, Y., & Le, W. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9070-5 · Cited by 2,190
Innate immunity in Alzheimer's disease
Heneka, M. T., Golenbock, D. T., & Latz, E. (2015) · Nature Immunology · doi:10.1038/ni.3102 · Cited by 902
Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease
Ferreira, S. T., Clarke, J. R., Bomfim, T. R., & De Felice, F. G. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.010 · Cited by 356
Targeting Astrocytes Ameliorates Neurologic Changes in a Mouse Model of Alzheimer's Disease
Furman, J. L., Sama, D. M., Gant, J. C., Beckett, T. L., Murphy, M. P., Bachstetter, A. D., Van Eldik, L. J., & Norris, C. M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2323-12.2012 · Cited by 313
Self-citationBachstetter, A. D., Van Eldik, L. J., Schmitt, F. A., Neltner, J. H., Ighodaro, E. T., Webster, S. J., Patel, E., Abner, E. L., Kryscio, R. J., & Nelson, P. T. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0209-z · Cited by 258
Self-citation
Metadata
- Authors
- Bachstetter, A. D., Norris, C. M., Sompol, P., Wilcock, D. M., Goulding, D., Neltner, J. H., St. Clair, D., Watterson, D. M., & Van Eldik, L. J.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2012-07-25
- Volume
- 32
- Issue
- 30
- Pages
- 10201-10210
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2056958351
- Cited by
- 107
- References
- 26
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.